IMFINZI® (durvalumab) plus chemotherapy approved in the US …
https://www.astrazeneca-us.com/media/press-releases/2022/imfinzi-durvalumab-plus-chemotherapy-approved-in-the-us-as-the-first-immunotherapy-regimen-for-patients-with-advanced-biliary-tract-cancer-09052022.html
WebSep 5, 2022 · IMFINZI® (durvalumab) plus chemotherapy approved in the US as the first immunotherapy regimen for patients with advanced biliary tract cancer. 5 September 2022. Approval based on TOPAZ-1 Phase III trial results, which showed IMFINZI combination reduced risk of death by 20% vs. chemotherapy alone.
DA: 27 PA: 52 MOZ Rank: 99